PMI back up to 59% in November

Israel's purchasing managers index rose more than 10 percentage points to 59% in November, after falling to 48.6% in October from 55.8% in September, Dun & Bradstreet Israel said Wednesday, attributing the fluctuation to the holiday period.

By DANIEL KENNEMER
December 15, 2005 07:45

 
X

Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later Don't show it again

Israel's purchasing managers index rose more than 10 percentage points to 59% in November, after falling to 48.6% in October from 55.8% in September, Dun & Bradstreet Israel said Wednesday, attributing the fluctuation to the holiday period. Values above 50% indicate growth in Israel's production market, while any drop beneath 50% indicates a slowdown. The renewed growth trend seen was influenced primarily by rises in production output and employment. Export demand grew 7.9 points to 61.5%, its highest value in the past year.

Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection

By GLOBES, NIV ELIS